Utility of the Behavior and Symptom Identification Scale (BASIS-32) at an Alcohol Detoxification Unit

Johnson, Mark; Brems, Christiane; Mills, Michael E.; Freemon, Melinda

doi:10.1300/j020v23n01_03

Cited by 3 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Relevant to the current study, psychiatric symptoms among drug users are widespread and often ignored despite research that gives evidence to the improved treatment process and outcomes of individuals who are correctly and comorbidly diagnosed (Cornelius, Bukstein, Salloum, & Clark, 2003;Cornelius et al, 1995;De Bernado, Newcomb, Toth, Richey, & Mendoza, 2002;Drake & Wallach, 2000). Use of psychiatric screening instruments is thus becoming increasingly common in substance abuse treatment settings, and the psychometric validation of such tools with these populations must be established (Johnson, Brems, Freemon, & Mills, 2005). The current study seeks to confirm the factor structure of the BDI-II with drug users to establish the appropriate interpretation of test results.…”

mentioning

confidence: 97%

Depression as Measured by the Beck Depression Inventory-II Among Injecting Drug Users

et al. 2006

Self Cite

View full text Add to dashboard Cite

This study conducts a confirmatory factor analysis of the Beck Depression Inventory-II (BDI-II) with a sample of 598 individuals who reported recent injecting drug use. Findings indicate that out of four models tested, the best model for this sample is a three-factor solution (somatic, affective, and cognitive) previously reported by Buckley, Parker, and Heggie. The findings that nearly 50% of participants provided BDI-II scores indicating significant depressive symptomatology reveals that these individuals are in need of treatment for their psychiatric symptoms as well as substance use. Somatic symptoms are endorsed more strongly than affective or cognitive symptoms of depression, suggesting a possible, but yet poorly defined, relationship between depressive symptomatology and drug use that centers on shared somatic symptomatology.

show abstract

mentioning

confidence: 97%